Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
EARLY_PHASE1
10
about 2.1 years
18+
1 site in MN
What this study is about
This trial is testing a treatment combination of dasatinib, quercetin, fisetin, and temozolomide in patients with glioma who have received previous treatments and have residual tumor cells. The goal is to determine if this combination is safe, tolerable, and effective for these patients.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Patient Observation
- 2.Take Dasatinib
- 3.Take Fisetin
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
dasatinib, dietary supplement, fluorodopa (18F), Immunological Agents, temozolomide
oral (Oral Tablet), injection, intravenous
Primary: Turnaround time for scan and marker data
Secondary: Incidence of adverse events
diagnostic, imaging